# A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

> **NCT06615479** · PHASE3 · RECRUITING · sponsor: **Juno Therapeutics, Inc., a Bristol-Myers Squibb Company** · enrollment: 440 (estimated)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma (RRMM)

## Interventions

- **DRUG:** BMS-986393
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Daratumumab
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Carfilzomib

## Key facts

- **NCT ID:** NCT06615479
- **Lead sponsor:** Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-12
- **Primary completion:** 2027-12-30
- **Final completion:** 2032-06-22
- **Target enrollment:** 440 (ESTIMATED)
- **Last updated:** 2026-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06615479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06615479, "A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT06615479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*